These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9241010)

  • 1. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
    Chouinard G; Albright PS
    J Clin Psychopharmacol; 1997 Aug; 17(4):298-307. PubMed ID: 9241010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID; Lemmens P; Vester-Blokland E
    Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
    Ganguly R; Miller LS; Martin BC
    Schizophr Res; 2003 Sep; 63(1-2):111-9. PubMed ID: 12892865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
    Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
    Int Clin Psychopharmacol; 2001 Nov; 16(6):325-30. PubMed ID: 11712620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
    Marder SR; Davis JM; Chouinard G
    J Clin Psychiatry; 1997 Dec; 58(12):538-46. PubMed ID: 9448657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
    Blin O; Azorin JM; Bouhours P
    J Clin Psychopharmacol; 1996 Feb; 16(1):38-44. PubMed ID: 8834417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of risperidone on affective symptoms in patients with schizophrenia.
    Peuskens J; Van Baelen B; De Smedt C; Lemmens P
    Int Clin Psychopharmacol; 2000 Nov; 15(6):343-9. PubMed ID: 11110010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
    Chue PS; Heeg B; Buskens E; van Hout BA
    Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
    Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA
    J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.